Research · Sep 3, 2026
[VRTX] Vertex Thesis 2026: Alyftrek Transition + CASGEVY Scaling + Journavx Launch Test Diversification
Vertex Pharmaceuticals FY2025 revenue ~$12B (+9-12%) with adj. operating margin sustained at ~50%+. CF franchise (~$11B, 94% of revenue) at penetration ceiling — ~80%+ global CF patient share with Trikafta dominant. Alyftrek (next-gen vanzacaftor/tezacaftor/deutivacaftor, FDA approved Dec 2024) once-daily formulation transitioning Trikafta patients. CASGEVY (first CRISPR-based therapy approved, gene therapy for sickle cell + beta thalassemia) commercial ramp ~$200-400M FY2025 — slower than initial projections on operational complexity (~6-12 months patient process). Journavx (suzetrigine sodium channel blocker for acute pain, FDA approved Jan 2025) commercial launch ramping. FY2026 thesis: Alyftrek transition succeeds preserving CF franchise; CASGEVY scaling toward $1B+ as ATC capacity scales; Journavx capturing US acute pain share; pipeline (povetacicept IgA nephropathy + VX-880 type 1 diabetes) progressing.